Long-term safety experience of Ixekizumab: results from more than 3 years of follow-up and more than 15000 patient-years of exposure to Ixekizumab

被引：0
|
作者：
Armstrong, A. [1 ]
Agada, N. [2 ]
Xu, W. [2 ]
Gallo, G. [2 ]
Schloebe, A. [3 ]
机构：
[1] USC, Keck Sch Med, Los Angeles, CA USA
[2] Eli Lilly & Co, Indianapolis, IN USA
[3] Lilly Deutschland GmbH, Bad Homburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P107
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] Long-term safety experience of ixekizumab: Results from more than 3 Years of follow-up and 15,000 patient-years of exposure to ixekizumab
    Armstrong, A.
    Agada, N.
    Xu, W.
    Gallo, G.
    Norman, J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 68 - 68
  • [2] Long-term safety of ixekizumab in patients with moderate-to-severe psoriasis: results from more than 17 000 patient-years of exposure
    Griffiths, C. E.
    Lebwohl, M. G.
    Blauvelt, A.
    Reich, K.
    Gooderham, M.
    Terui, T.
    Agada, N.
    Xu, W.
    Gallo, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 5 - 6
  • [3] Safety and Tolerability of Ixekizumab: Integrated Analysis of Safety in Patients With Moderate-to-Severe Psoriasis From 11 Clinical Trials with More Than 12000 Patient-Years of Exposure to Ixekizumab
    Langley, Richard
    Nakagawa, Hidemi
    Agada, Noah
    Xu, Isabel Wen
    Pangallo, Beth
    Reich, Kristian
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 17 - 17
  • [4] Safety and tolerability of ixekizumab: integrated analysis of safety in patients with moderate-to-severe psoriasis with more than 7800 patient-years of exposure to ixekizumab from 7 clinical trials
    Kimball, A.
    Langley, R.
    Ohtsuki, M.
    Moriarty, S. R.
    Xu, W., I
    Mallbris, L.
    Leutz, A.
    Reich, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 110 - 111
  • [5] Long-term follow-up more than 10 years after HSCT: a monocentric experience
    Jessica Frau
    Margherita Carai
    Giancarlo Coghe
    Giuseppe Fenu
    Lorena Lorefice
    Giorgio La Nasa
    Elena Mamusa
    Adriana Vacca
    Maria Giovanna Marrosu
    Eleonora Cocco
    Journal of Neurology, 2018, 265 : 410 - 416
  • [6] Long-term follow-up more than 10 years after HSCT: a monocentric experience
    Frau, Jessica
    Carai, Margherita
    Coghe, Giancarlo
    Fenu, Giuseppe
    Lorefice, Lorena
    La Nasa, Giorgio
    Mamusa, Elena
    Vacca, Adriana
    Marrosu, Maria Giovanna
    Cocco, Eleonora
    JOURNAL OF NEUROLOGY, 2018, 265 (02) : 410 - 416
  • [7] Long-term results of synovectomy for rheumatoid elbow with more than 10 years follow-up
    Ishii, K.
    Inaba, Y.
    Saito, T.
    Aratake, M.
    Nakashima, K.
    Kobayashi, N.
    Kawakami, Y.
    Matsuo, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 354 - 354
  • [8] Long-term results of Amatsu tracheoesophageal shunt: Follow-up of more than 5 years
    Matsui, Hidetoshi
    Iwae, Shigemichi
    Hirayama, Yuji
    Yonezawa, Koichiro
    Shigeji, Jun
    LARYNGOSCOPE, 2018, 128 (06): : 1395 - 1397
  • [9] Diabetes insipidius from neurosarcoidosis: Long-term follow-up for more than eight years
    Tabuena, RP
    Nagai, S
    Handa, T
    Shigematsu, M
    Hamada, K
    Ito, I
    Izumi, T
    Mishima, M
    Sharma, OP
    INTERNAL MEDICINE, 2004, 43 (10) : 960 - 966
  • [10] Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    Armstrong, April
    Paul, Carle
    Puig, Luis
    Boehncke, Wolf Henning
    Freeman, Michael
    Torii, Hideshi
    Papp, Kim
    Griffiths, Christopher E. M.
    Blauvelt, Andrew
    Reich, Kristian
    Gooderham, Melinda
    Terui, Tadashi
    Renda, Lisa
    Agada, Noah
    Xu, Wen
    Gallo, Gaia
    Lebwohl, Mark G.
    DERMATOLOGY AND THERAPY, 2020, 10 (01) : 133 - 150
12345